

**Amendments to the Claims**

The following listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claims 1-32 (cancelled).

33 (previously presented): A method of inhibiting IL-17C activity in a subject with psoriasis, comprising administering to the subject a binding composition, wherein the binding composition comprises an antigen binding site of an antibody that specifically binds to a human IL-17C protein and blocks binding of the IL-17C protein to the extracellular domain of a human IL-17RE protein, wherein the human IL-17C protein comprises the mature sequence in SEQ ID NO:24 and the extracellular domain of the human IL-17RE protein comprises amino acids 1-424 of SEQ ID NO:12.

34 (currently amended): The method of Claim 33 24, wherein the antibody is:

- a) a polyclonal antibody;
- b) a monoclonal antibody; or
- c) a humanized antibody

35 (previously presented): The method of Claim 33, wherein the antibody is a humanized antibody.